Physician profile
Manav Singla
NPI 1801996079
$168,108.88
in general payments reported to CMS, 2019-2025
49 companies · $40K in 2025
The $40K reported for 2025 was more than what 95% of Allergy & Immunology providers received nationally (typical 2025 total: $1,138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $29K · 2020: $14K · 2021: $18K · 2022: $11K · 2023: $34K · 2024: $22K · 2025: $40K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $64K · Food and Beverage: $12K · Consulting Fee: $11K · Honoraria: $6,663 · Travel and Lodging: $2,506 · Education: $215.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $63,867.00 |
| Food and Beverage | $12,190.34 |
| Consulting Fee | $11,425.97 |
| Honoraria | $6,663.00 |
| Travel and Lodging | $2,506.43 |
| Education | $215.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $69,761.96 | 2019-2025 | |
| Glaxosmithkline, LLC. | $44,031.12 | 2019-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $12,565.70 | 2019-2023 | Spiriva Respimat |
| Alk-Abello, INC | $11,870.49 | 2019-2025 | Odactra, Ragwitek, Grastek |
| Regeneron Healthcare Solutions, INC. | $5,507.96 | 2019-2025 | Dupixent |
| Teva Pharmaceuticals USA, INC. | $4,262.40 | 2019-2024 | Airduo Digihaler, Albuterol Sulfate |
| Regeneron Pharmaceuticals, INC. | $3,275.45 | 2019-2025 | Dupixent |
| Novartis Pharmaceuticals Corporation | $3,119.87 | 2019-2025 | |
| Blueprint Medicines Corporation | $2,653.67 | 2022-2025 | Ayvakit |
| Genentech USA, INC. | $2,374.39 | 2019-2025 | Xolair |
| Astrazeneca Pharmaceuticals LP | $1,892.41 | 2019-2025 | Fasenra, Tezspire, Breztri |
| Csl Behring | $815.64 | 2019-2025 | Hizentra, Andembry, Haegarda |
| Pfizer INC. | $792.12 | 2019-2025 | |
| Grifols USA, LLC | $739.96 | 2019-2025 | Xembify, Prolastin-C Liquid |
| Optinose US, INC. | $437.62 | 2019-2024 |
Show all 47 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kaleo, INC. | $437.02 | 2019-2024 | Auvi-Q |
| Takeda Pharmaceuticals U.S.A., INC. | $402.89 | 2020-2025 | Takhzyro, Cuvitru, Glassia |
| Abbvie INC. | $400.01 | 2021-2025 | Rinvoq |
| Amgen INC. | $393.40 | 2021-2025 | Tezspire, Otezla |
| Octapharma USA, INC. | $383.58 | 2019-2024 | Cutaquig, Panzyga |
| Sanofi-Aventis U.S. LLC | $243.59 | 2019-2025 | |
| Biocryst US Sales Co., LLC | $193.02 | 2021-2025 | Orladeyo |
| Greer Laboratories, INC. | $189.41 | 2023-2025 | Oralair |
| Bio Products Laboratory USA, INC. | $187.86 | 2019-2023 | Gammaplex, Coagadex |
| Pharming Healthcare, INC. | $144.45 | 2019-2025 | Ruconest |
| Lilly USA, LLC | $141.29 | 2025 | Taltz, Ebglyss |
| Incyte Corporation | $129.11 | 2021-2024 | Opzelura |
| Ars Pharmaceuticals Operations, INC. | $103.58 | 2025 | Neffy |
| Aimmune Therapeutics, INC. | $73.27 | 2021-2022 | |
| Shire North American Group INC | $66.58 | 2019 | |
| Phadia US INC. | $53.49 | 2019 | |
| Merck Sharp & Dohme LLC | $52.98 | 2019-2022 | |
| Ionis Pharmaceuticals, INC. | $52.24 | 2025 | Dawnzera |
| Organon LLC | $50.99 | 2025 | Vtama |
| Mylan Specialty L.P. | $39.15 | 2021-2023 | Yupelri |
| Galderma Laboratories, L.P. | $36.09 | 2025 | Nemluvio |
| Covis Pharma Gmbh | $35.35 | 2019 | |
| Horizon Therapeutics Plc | $29.62 | 2020 | |
| Adma Biomanufacturing LLC | $24.47 | 2025 | |
| Biocryst Pharmaceuticals, INC. | $23.57 | 2020 | |
| Cycle Pharmaceuticals INC | $23.29 | 2025 | Sajazir |
| Genentech, INC. | $21.75 | 2024 | Xolair |
| Sunovion Pharmaceuticals INC. | $18.10 | 2019 | |
| Hikma Pharmaceuticals USA | $15.79 | 2024 | Ryaltris |
| Leo Pharma INC. | $15.49 | 2022 | |
| Verona Pharma, INC. | $14.18 | 2025 | Ohtuvayre |
| Eyevance Pharmaceuticals LLC | $12.51 | 2021 |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Manav Singla listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.